医学
狭缝
安慰剂
荟萃分析
舌下免疫疗法
不利影响
人口
内科学
随机对照试验
舌下给药
系统回顾
皮肤病科
梅德林
免疫疗法
免疫学
替代医学
病理
癌症
环境卫生
生物
法学
遗传学
政治学
作者
Dominika Boldovjáková,Sara Cordoni,Craig John Fraser,A. Love,Lorna Patrick,G Ramsay,Aaron Stephen James Ferguson,Anas Gomati,Bhaskar Ram
摘要
Abstract Introduction Allergic rhinitis (AR) is a common inflammatory condition of the nasal mucosa affecting approximately 20% of the population worldwide. Current therapies include intranasal antihistamines, corticosteroids, subcutaneous and sublingual immunotherapy (SLIT). This review and meta‐analysis assess the efficacy of SLIT in the management of grass pollen‐induced AR in adults. Methods Ovid EMBASE, Ovid EBM Reviews, Cochrane Central Register of Controlled Trials, Ovid MedLine and PubMed were searched using the following terms: ‘sublingual immunotherapy’, ‘SLIT’, ‘rhinitis’, ‘allergic rhinitis’, ‘rhinosinusitis’ and ‘rhino‐conjunctivitis’. All included studies were double‐blind, placebo‐controlled and randomised trials. Primary outcome was symptom score and secondary outcome included quality of life and safety profile. Meta‐analysis of symptom improvement was carried out. Results Six studies were identified with 979 subjects randomly allocated to SLIT and 992 to a placebo control. All studies reported an improvement in symptoms with SLIT, with five reaching statistical significance ( P < .05). Four studies reported statistically significant improvement in quality of life ( P < .05). Oral pruritus was the most common adverse event reported. The overall risk of bias was high in 50% of the studies. Conclusions Sublingual immunotherapy was a safe and effective treatment for grass pollen‐induced AR in adults, and therefore, consideration should be given to its use for moderate‐to‐severe disease in the UK‐wide population.
科研通智能强力驱动
Strongly Powered by AbleSci AI